QuantaMatrix Inc.

KOSDAQ:A317690 Stock Report

Market Cap: ₩159.1b

QuantaMatrix Past Earnings Performance

Past criteria checks 0/6

QuantaMatrix has been growing earnings at an average annual rate of 14.6%, while the Biotechs industry saw earnings growing at 7.2% annually. Revenues have been growing at an average rate of 63.6% per year.

Key information

14.6%

Earnings growth rate

42.0%

EPS growth rate

Biotechs Industry Growth11.7%
Revenue growth rate63.6%
Return on equity-160.4%
Net Margin-497.8%
Last Earnings Update30 Jun 2024

Recent past performance updates

No updates

Recent updates

Is QuantaMatrix (KOSDAQ:317690) Using Debt In A Risky Way?

Jul 19
Is QuantaMatrix (KOSDAQ:317690) Using Debt In A Risky Way?

What Type Of Shareholders Make Up QuantaMatrix Inc.'s (KOSDAQ:317690) Share Registry?

Mar 10
What Type Of Shareholders Make Up QuantaMatrix Inc.'s (KOSDAQ:317690) Share Registry?

Revenue & Expenses Breakdown

How QuantaMatrix makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSDAQ:A317690 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 243,605-17,94313,5275,200
31 Mar 243,483-20,22114,3765,361
31 Dec 233,118-21,55615,5505,778
30 Sep 231,606-20,46913,8756,067
30 Jun 231,460-19,68813,3185,806
31 Mar 231,333-19,53713,4315,608
31 Dec 221,286-19,23712,8375,492
30 Sep 221,098-20,08313,4645,308
30 Jun 22901-19,67213,0335,144
31 Mar 22789-19,05712,2675,077
31 Dec 21550-18,11611,4065,122
30 Sep 21673-16,59410,7884,572
30 Jun 21665-15,96310,0434,556
31 Mar 211,736-15,0739,1834,717
31 Dec 201,689-14,6598,5674,776
30 Sep 201,885-15,5698,8415,488
30 Jun 201,834-17,0238,7385,736
31 Mar 20709-40,7918,4675,638
31 Dec 19811-63,8118,1235,202
31 Dec 1885-16,0096,1114,050
31 Dec 1747-12,4234,2473,459

Quality Earnings: A317690 is currently unprofitable.

Growing Profit Margin: A317690 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: A317690 is unprofitable, but has reduced losses over the past 5 years at a rate of 14.6% per year.

Accelerating Growth: Unable to compare A317690's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A317690 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (6.1%).


Return on Equity

High ROE: A317690 has a negative Return on Equity (-160.36%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies